LEWIS JOEL

About LEWIS JOEL

Joel Lewis is the Chief Executive Officer and President of Galectin Therapeutics Inc., a Nasdaq-listed biotechnology company focused on developing novel therapies for chronic liver disease and cancer. He joined the company’s Board of Directors in 2017 and was later appointed CEO and President in September 2020, marking a progression from governance oversight to day-to-day executive leadership. In this role, he is responsible for corporate strategy and operational oversight, with a particular focus on Galectin’s global NASH-RX clinical trial, which is designed to prevent varices in patients with NASH cirrhosis using the company’s proprietary galectin-3 inhibitor belapectin (GR-MD-02). ([investor.galectintherapeutics.com](https://investor.galectintherapeutics.com/news-releases/news-release-details/galectin-therapeutics-appoints-joel-lewis-chief-executive?utm_source=openai)) Lewis brings more than 25 years of financial and corporate management experience to the role. He began his career in public accounting in 1992, building a foundation in accounting, taxation, and financial controls. From 1998 to 2001, he served as a Tax Manager at Deloitte & Touche, followed by a position as Tax and Accounting Manager at Century America LLC from 2001 to 2006. He then spent 2007 through 2019 as Managing Director of Shareholder Services at Uline, Inc., where he likely worked on shareholder-related matters, capital structure issues, and broader corporate administration. This background points to deep experience in finance, governance, compliance, and strategic execution, all highly relevant to leading a clinical-stage biotechnology company. ([investor.galectintherapeutics.com](https://investor.galectintherapeutics.com/management/?utm_source=openai)) Since taking the helm, Lewis has been associated with Galectin’s emphasis on advancing its lead clinical program and strengthening execution discipline. His profile is that of a finance-oriented executive who moved into a chief executive role, bringing a combination of fiscal rigor, stakeholder management, and oversight of complex clinical-development initiatives. For investors and corporate governance audiences, his career reflects a leadership style grounded in operational focus, board experience, and long-term value creation in a highly regulated sector. ([investor.galectintherapeutics.com](https://investor.galectintherapeutics.com/news-releases/news-release-details/galectin-therapeutics-appoints-joel-lewis-chief-executive?utm_source=openai))